Bank Of America Corp Bio Atla, Inc. Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Bio Atla, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 40,050 shares of BCAB stock, worth $62,878. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,050

Previous 1,155 3367.53%

Holding current value

$62,878

Previous $1,000 6900.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.17 - $2.05 $45,507 - $79,734	38,895 Added 3367.53%	40,050 $70,000
Q2 2024 Aug 14, 2024	SELL	$1.37 - $3.92 $19,143 - $54,774	-13,973 Reduced 92.37%	1,155 $1,000
Q1 2024 May 15, 2024	SELL	$1.88 - $3.46 $53,674 - $98,783	-28,550 Reduced 65.36%	15,128 $52,000
Q4 2023 Feb 14, 2024	BUY	$1.27 - $3.18 $29,049 - $72,739	22,874 Added 109.95%	43,678 $107,000
Q2 2023 Aug 14, 2023	BUY	$2.83 - $3.87 $2,255 - $3,084	797 Added 3.98%	20,804 $62,000
Q1 2023 May 12, 2023	SELL	$2.3 - $8.25 $64,480 - $231,288	-28,035 Reduced 58.36%	20,007 $53,000
Q4 2022 Feb 10, 2023	SELL	$6.29 - $11.01 $24,732 - $43,291	-3,932 Reduced 7.57%	48,042 $396,000
Q3 2022 Nov 14, 2022	SELL	$2.94 - $11.87 $341 - $1,376	-116 Reduced 0.22%	51,974 $400,000
Q2 2022 Aug 12, 2022	SELL	$2.13 - $5.38 $123,001 - $310,678	-57,747 Reduced 52.58%	52,090 $0
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $289,382 - $1.24 Million	66,069 Added 150.95%	109,837 $549,000
Q4 2021 Feb 08, 2022	BUY	$19.0 - $30.95 $655,576 - $1.07 Million	34,504 Added 372.45%	43,768 $859,000
Q3 2021 Nov 15, 2021	SELL	$29.44 - $43.74 $47,221 - $70,158	-1,604 Reduced 14.76%	9,264 $273,000
Q2 2021 Sep 13, 2021	BUY	$38.07 - $56.17 $413,744 - $610,455	10,868 New	10,868 $461,000

Others Institutions Holding BCAB

# of Institutions

Shares Held

17.3M

Call Options Held

500

Put Options Held

33.5K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $57M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Bio Atla, Inc. Transaction History